ArticleEuropean urology open science2024
Suitability of the MP1000 Platform for Robot-assisted Prostatectomy: A Prospective Randomised Controlled Trial.
Article in European urology open science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Perioperative efficacy and safety of the MP1000 robotic surgical system versus the da Vinci robotic surgical system in urologic surgery: a systematic review and meta-analysis.Journal of robotic surgery · 2026Pooled it
- Outcomes of robot-assisted radical prostatectomy with novel robotic platforms vs da Vinci multiport systems: a systematic review and network meta-analysis.Prostate cancer and prostatic diseases · 2026Pooled it
- A systematic review and meta-analysis of prospective studies comparing perioperative outcomes between the MP1000 and Da Vinci surgical systems for robot-assisted partial nephrectomy.Journal of robotic surgery · 2026Pooled it
- Robot-assisted partial nephrectomy and robot-assisted radical prostatectomy using the Chinese surgical systems KangDuo-SR-2000 and EDGE MP1000 versus the Da Vinci Xi system: a prospective, single-center, non-randomized clinical trial.World journal of urology · 2025Trial
- Feasibility and preliminary safety of urologic telesurgery using Chinese surgical systems: a single-center exploratory case series.BMC urology · 2026Article
- Safety and efficacy of the Chinese surgical robotic system (EDGE MP1000 & MP2000) for robot-assisted radical prostatectomy: results from a single high-volume center.Journal of robotic surgery · 2026Article
- Short- and long-term outcomes of totally robotic versus robotic-assisted total gastrectomy for advanced gastric cancer: a single-center retrospective study.World journal of surgical oncology · 2025Article
- Comparable perioperative performance between three robotic system for robot-assisted partial nephrectomy to treat early renal cancer.Scientific reports · 2025Article
- Advancing surgical techniques: a first application of remote robotic pancreaticoduodenectomy for resectable malignant tumor.Hepatobiliary surgery and nutrition · 2025Article
- New surgical robotic platforms in China and their applications in urologic surgeries.Asian journal of urology · 2025Article
- Safety and efficacy of the MP1000 surgical system in robot-assisted radical cystectomy: A prospective study.Bladder (San Francisco, Calif.) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: Robot-assisted radical prostatectomy (RARP) is widely used because of the many advantages of a robotic approach. The da Vinci Si robot is one of the most commonly used surgical robot systems, but it may be associated with higher costs owing to the use of consumable surgical supplies. Our aim was to conduct a preliminary investigation of the capability of the MP1000 system for RARP. Methods: In this prospective, multicentre, single-blinded study, we randomly assigned 42 patients scheduled to undergo RARP between April and September 2021 to a da Vinci Si group (control) or an MP1000 group (intervention). Patients underwent RARP performed using the assigned robotic system and were followed up at 3-mo intervals. The primary outcome was the rate of conversion to open/laparoscopic surgery. Secondary outcomes were installation and operation times, intraoperative blood loss, postoperative surgical margin status, hospital stay, incontinence, complications, safety indicators, and surgeon ergonomics. Key findings and limitations: All procedures were successfully completed without conversion to open/laparascopic surgery or major complications. Secondary outcomes, including oncological and ergonomic indicators, did not differ significantly between the groups over the study period. One patient in the control group experienced dysuria (Clavien-Dindo grade 3). No patients had incontinence at 3 mo. A limitation of the study is the small sample size. Conclusions and clinical implications: RARP with the MP1000 system is feasible, safe, and effective in the management of localised prostate cancer. Patient summary: We assessed the effectiveness and safety of the new MP1000 robot system for robot-assisted removal of the prostate in comparison to the da Vinci Si robot. We found no difference in effectiveness or safety among 42 patients with prostate cancer who were assigned randomly to one of the two systems. We conclude that the MP1000 is a suitable robot for this surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.